- Home
- NPFD vs CMPX Comparison
NPFD vs CMPX Comparison
Compare NPFD & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPFD
- CMPX
- Stock Information
- Founded
- NPFD 2021
- CMPX 2014
- Country
- NPFD United States
- CMPX United States
- Employees
- NPFD N/A
- CMPX N/A
- Industry
- NPFD Trusts Except Educational Religious and Charitable
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- NPFD Finance
- CMPX Health Care
- Exchange
- NPFD Nasdaq
- CMPX Nasdaq
- Market Cap
- NPFD 455.5M
- CMPX 408.6M
- IPO Year
- NPFD N/A
- CMPX N/A
- Fundamental
- Price
- NPFD $18.75
- CMPX $2.24
- Analyst Decision
- NPFD
- CMPX Strong Buy
- Analyst Count
- NPFD 0
- CMPX 7
- Target Price
- NPFD N/A
- CMPX $12.43
- AVG Volume (30 Days)
- NPFD 64.7K
- CMPX 1.8M
- Earning Date
- NPFD 01-01-0001
- CMPX 05-12-2025
- Dividend Yield
- NPFD 6.28%
- CMPX N/A
- EPS Growth
- NPFD N/A
- CMPX N/A
- EPS
- NPFD N/A
- CMPX N/A
- Revenue
- NPFD N/A
- CMPX $850,000.00
- Revenue This Year
- NPFD N/A
- CMPX $47.65
- Revenue Next Year
- NPFD N/A
- CMPX $3,909.48
- P/E Ratio
- NPFD N/A
- CMPX N/A
- Revenue Growth
- NPFD N/A
- CMPX N/A
- 52 Week Low
- NPFD $14.50
- CMPX $0.77
- 52 Week High
- NPFD $18.07
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- NPFD 44.25
- CMPX 44.45
- Support Level
- NPFD $18.75
- CMPX $2.18
- Resistance Level
- NPFD $18.98
- CMPX $2.17
- Average True Range (ATR)
- NPFD 0.14
- CMPX 0.22
- MACD
- NPFD 0.01
- CMPX -0.02
- Stochastic Oscillator
- NPFD 47.73
- CMPX 68.16
About NPFD Nuveen Variable Rate Preferred & Income Fund
Nuveen Variable Rate Preferred&Income is a newly organized, diversified, closed-end management investment company. The Fund's investment objective is to seek to provide a high level of current income and total return.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.